Nymox Pharma (NYMX) Reports Q1 EPS of $0.04

Nymox Pharma (NASDAQ: NYMX) reported Q1 EPS of $0.04, versus ($0.07) reported last year. Revenue for the quarter came in at $75.4 thousand, versus $78.2 thousand reported last year.

The net income in 2015 is attributable to the recognition of $2,508,533 as revenue relating to the upfront payment received from Recordati in December 2010 compared with $654,400 for the quarter ended March 31, 2014. The increase of $1,854,133 in the first quarter of 2015 is due to the fact that the initial estimated service period of five years to recognize the upfront payment was modified following Recordati's termination of the European clinical trial. Consequently, the Corporation recognized, as revenue, an amount of $2,508,533 which represented the remaining deferred revenue relating to the upfront payment received in December 2010.

Excluding the additional $1,854,133 deferred revenue recognized as revenue, the Corporation would have incurred a net loss of $277,582 for the quarter ended March 31, 2015 compared to net loss of $2,592,816 for the same period in 2014. The decrease is mainly due to stock compensation charges of $16,551 in 2015 compared to $1,420,185 in 2014 combined to a reduction of $492,432 in clinical trial expenditures related to NX-1207 studies. The basic and diluted weighted average number of common shares outstanding for the quarter ended March 31, 2015 were 36,272,978 and 38,280,483 respectively, compared to basic and diluted weighted average number of common shares of 34,797,302 at March 31, 2014.

For earnings history and earnings-related data on Nymox Pharma (NYMX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c